DNA-repair pathway inhibitors for the treatment of ovarian cancer

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Martinek, Igor ^a   Gaitskell, Kezia ^b   Haldar, Krishnayan ^a   Nicum, Shibani ^c   Kehoe, Sean ^a   Morrison, Jo ^d  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c NHS Department of Oncology Oxford Cancer and Haematology Centre   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; ANTINEOPLASTIC AGENT; ATM PROTEIN; ATM PROTEIN INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA DEPENDENT PROTEIN KINASE; DNA DEPENDENT PROTEIN KINASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ALOPECIA; ANEMIA; ANOREXIA; BLEEDING; CANCER GRADING; DIARRHEA; DNA REPAIR; DRUG EFFICACY; DRUG HYPERSENSITIVITY; HUMAN; INTERVENTION STUDY; LEUKOPENIA; MUCOSA ILAMMATION; NAUSEA; NEUTROPENIA; OVARY CANCER; PROCTITIS; PROGRESSION FREE SURVIVAL; REVIEW; RISK ASSESSMENT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; VOMITING; ALLERGY; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DNA DAMAGE; GASTROINTESTINAL SYMPTOM; GENETIC PREDISPOSITION; MUCOSA INFLAMMATION; NEUROLOGIC DISEASE; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SYSTEMATIC REVIEW;

EID: 70049104552     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007929     Document Type: Review

References (24)

1. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al.Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434(7035):913-917 (Pubitemid 40559005)
2. Bryant HE, Helleday T. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Research 2006;34(6):1685-1691
3. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The Results of Direct and Indirect Treatment Comparisons in Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Epidemiology 1997;Vol.50(No.6):683-691 (Pubitemid 27341818)
4. Cancer Therapy Evaluation Program (CTEP), Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. (http://ctep.cancer.gov) 2006.
5. Curtin NJ. PARP inhibitors for cancer therapy. Expert Reviews in Molecular Medicine 2005;7(4):1-20.
6. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. London: BMJ Publication group, 2001.
7. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-188
8. Engel J, Eckel R, Schubert-Fritschle G, Kerr J, Kuhn W, Diebold J, et al.Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. http://info.cancerresearchuk.org/ cancerstats/types/ovary/survival/ 2002;38(18):2435-2445
9. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al.Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434(7035):917-921 (Pubitemid 40559006)
10. Fong PC, Boss DS, Carden CP, Roelvink M, De Greve J, Gourley CM, et al.AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study. Journal of Clinical Oncology 2008;26(May 20 suppl):abstr 5510.
11. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase. Lyon: IARCPress, 2004, issue No.5. version 2.0.
12. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-560
13. Higgins JPT, Green S (editors). Cochrane Handbook for systematic reviews of interventions. Version 5.0.0 [updated September 2008]. Available from www.cochrane-handbook.org.
14. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. National Reviews of Drug Discovery 2005;4(5):421-440 (Pubitemid 40704125)
15. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al.Cancer statistics. A Cancer Journal for Clinicians 2008;58(2):71-96.
16. Morrison J, Swanton A, Collins S, Kehoe S. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD005343] (Pubitemid 351805181)
17. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-2834 (Pubitemid 28562978)
18. Peralta-Leal A, Rodriguez MI, Oliver FJ. Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment. Clinical Translations in Oncology 2008;10(6):318-323
19. Quinn M, Babb B, Brock A, Jones J. In: Statistics OfN editor(s). Cancer Trends in England and Wales. London: The Stationery Office, 2001.
20. Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clinical Cancer Research 2007;13(5):1383-1388 (Pubitemid 46450426)
21. Shepherd JH. Revised FIGO staging for gynaecological cancer. British Journal of Obstetrics and Gynaecology 1989;96(8):889-92..
22. Stewart L, Advanced Ovarian Cancer Trialists Group. Chemotherapy for advanced ovarian cancer. Cochrane Database of Systematic Reviews 1999, Issue 1. [Art. No.: CD001418 DOI: 10.1002/14651858.CD001418; : ; : ]
23. Vergote I, Tropé CG, Amant F, Kristensen GB, Sardi JE, Ehlen T, et al.EORTC-GCG/NCIC-CTG Randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer (OVCA). Proceedings of the 12th Biennial Meeting of the International Gynecologic Cancer Society - IGCS. Bangkok, 2008.
24. Zaremba T, Curtin NJ. PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med Chem 2007;7(5):515-523 (Pubitemid 351836123)